Purpose: Cisplatin, a widely used chemotherapeutic agent, is known for its efficacy against various malignancies including ovarian, testicular, and solid tumors of the head and neck. Its role as a radiosensitizer is also well established. Cisplatin has several side effects including nephrotoxicity, neurotoxicity, hepatotoxicity, and ototoxicity. AQ1 However, its rare toxicity includes the development of cardiotoxicity, which can range from subclinical changes to life-threatening cardiac dysfunction.Method: Cisplatin-induced cardiotoxicity encompasses a spectrum of cardiac manifestations, including systolic dysfunction, arrhythmias, myocardial ischemia, and heart failure. We are presenting two patients who were started on cisplatin based chemotherapy. One of the patients developed vasospastic angina and the other developed sinus bradycardia along with dizziness, leading to stoppage of cisplatin.Results: Post withholding cisplatin, the cardiovascular symptoms normalized, and the electrocardiographic changes also reverted to normal. Early recognition through cardiac monitoring, including echocardiography and electrocardiography, is crucial for timely intervention. Management strategies involve discontinuation of cisplatin, supportive care, and appropriate heart failure treatment.Conclusion: This case series aims to present a collection of clinical cases that illustrate the diverse manifestations of cisplatin-induced cardiotoxicity, highlighting the importance of early recognition, risk stratification, and appropriate management strategies. Further experimental therapies maybe tried for preventing cisplatin cardiotoxicity.